Jing Liu

Dr. Liu has over 10 years of experience in medicinal chemistry and drug discovery. He received his PhD in organic chemistry from Brigham Young University in 2007 and completed his post-doctoral training at the University of Utah in 2009. His PhD and postdoctoral research focused on natural product total synthesis. Dr. Liu started his medicinal chemistry career at the Center for Integrative Chemical Biology and Drug Discovery at the University of North Carolina at Chapel Hill, where he contributed to the development of a series of first-in-class MERTK inhibitors, which led to an investigational drug in human clinical trials. In 2013, he joined Glycan Therapeutics as a Principal Scientist. He was in charge of the chemoenzymatic synthesis of novel structure-defined low-molecular-weight heparin sulfate oligosaccharides. In 2014, he was recruited to the Department of Pharmacological Sciences at the Icahn School of Medicine at Mount Sinai as an assistant professor. His research work led to the discovery of multiple potent and selective methyltransferase inhibitors, GPCR modulators, and protein degraders. In 2018, Dr. Liu joined Cullgen and established its Medicinal Chemistry Department. Dr. Liu’s has published 39 peer-reviewed journal articles. He is also an inventor of 18 issued U.S. patents and published PCT patent applications.